Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.32 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1400395 | 0.74 | AKR1C3 (0.39) | AKR1C3AKR1C2SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL22335505 | 0.74 | TSHR (0.31) | PPARA | |
| SCHEMBL9260962 | 0.70 | LMNA (0.46) | AKR1C3AKR1C2ALDH1A1AKR1C1PTGS1 | |
| SCHEMBL28988131 | 0.70 | LMNA (0.32) | — | |
| SCHEMBL28772896 | 0.69 | AKR1C3 (0.44) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL896359 | 0.68 | AKR1C3 (0.38) | AKR1C3AKR1C2SMN1; SMN2ALDH1A1AKR1C1 | |
| SCHEMBL895506 | 0.68 | L3MBTL1 (0.42) | AKR1C3AKR1C2MAPK1AKR1C1PTGS1 | |
| SCHEMBL3542896 | 0.67 | LMNA (0.30) | — | |
| SCHEMBL30937584 | 0.66 | TDP1 (0.35) | — | |
| SCHEMBL474100 | 0.66 | ALDH1A1 (0.46) | SMN1; SMN2ALDH1A1MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | PLPBP, PNPO, PDXK | AKR1C3 2050/4885AKR1C2 2260/4885SMN1; SMN2 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.